Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, California 90089, United States.
Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, California 90095, United States.
ACS Chem Biol. 2020 Aug 21;15(8):2299-2310. doi: 10.1021/acschembio.0c00537. Epub 2020 Jul 28.
Engineering T cells and natural killer (NK) cells with anti-HIV chimeric antigen receptors (CAR) has emerged as a promising strategy to eradicate HIV-infected cells. However, current anti-HIV CARs are limited by targeting a single epitope of the HIV envelope glycoprotein gp160, which cannot counter the enormous diversity and mutability of viruses. Here, we report the development of a universal CAR-NK cell, which recognizes 2,4-dinitrophenyl (DNP) and can subsequently be redirected to target various epitopes of gp160 using DNP-conjugated antibodies as adaptor molecules. We show that this CAR-NK cell can recognize and kill mimic HIV-infected cell lines expressing subtypes B and C gp160. We additionally find that anti-gp160 antibodies targeting membrane-distal epitopes (including V1/V2, V3, and CD4bs) are more likely to activate universal CAR-NK cells against gp160 target cells, compared with those targeting membrane-proximal epitopes located in the gp41 MPER. Finally, we confirm that HIV-infected primary human CD4 T cells can be effectively killed using the same approach. Given that numerous anti-gp160 antibodies with different antigen specificities are readily available, this modular universal CAR-NK cell platform can potentially overcome HIV diversity, thus providing a promising strategy to eradicate HIV-infected cells.
工程化 T 细胞和自然杀伤 (NK) 细胞,使其带有抗 HIV 的嵌合抗原受体 (CAR),已成为消除 HIV 感染细胞的一种很有前途的策略。然而,目前的抗 HIV CAR 受到靶向 HIV 包膜糖蛋白 gp160 单一表位的限制,无法应对病毒的巨大多样性和变异性。在这里,我们报告了一种通用的 CAR-NK 细胞的开发,该细胞识别 2,4-二硝基苯(DNP),随后可以使用 DNP 缀合的抗体作为衔接分子重新定向到针对 gp160 的各种表位。我们表明,这种 CAR-NK 细胞可以识别和杀死表达 B 和 C 亚型 gp160 的模拟 HIV 感染的细胞系。我们还发现,与靶向位于 gp41 MPER 中的膜近端表位的抗体相比,靶向膜远端表位(包括 V1/V2、V3 和 CD4bs)的抗 gp160 抗体更有可能激活针对 gp160 靶细胞的通用 CAR-NK 细胞。最后,我们证实可以使用相同的方法有效杀死感染 HIV 的原代人 CD4 T 细胞。鉴于有许多具有不同抗原特异性的抗 gp160 抗体随时可用,这种模块化的通用 CAR-NK 细胞平台有可能克服 HIV 的多样性,从而为消除 HIV 感染细胞提供了一种很有前途的策略。